Project description
An affordable cell engineering technology
Engineering immune cells to fight cancer has generated promising results, providing a therapeutic opportunity where chemotherapy fails. However, cell therapies are very expensive to manufacture, necessitating more cost-effective engineering methods. The mission of the EU-funded SOLUPORE project is to produce the next generation of cellular therapies at an improved cost. The SOLUPORE platform does not use viral vectors but a novel technology for delivering mRNA, DNA or proteins to primary T and NK cells, retaining high cell viability and functionality. The simplicity of the SOLUPORE method renders it user-friendly and applicable to the manufacture of immunotherapies.
Objective
There is encouraging news for cancer patients, a new treatment, cell immunotherapy, has been delivering spectacular
clinical results and is a game changer because it is an entirely new way of treating cancer. Cancer immunotherapy, in which
a patient’s own immune cells are ‘armed’ by cell engineering to target and kill cancer cells, gives levels of complete response
in patients. The first cell immunotherapy drug was approved in August 2017 at a price of $475,000 per treatment. To bring
these life-changing treatments to patients and relieve the European and global healthcare burden they must become
available at affordable costs. The one thing worse than failure is unaffordable success and the challenge with these
treatments is the complex and high-cost of manufacturing. Current cell engineering methods are very expensive to
manufacture. Avectas has developed Solupore, a cell engineering technology, which delivers cargo to cells and plays a
critical role in the manufacturing process. The technology works by temporarily making the cell membrane permeable and
allowing cargo into the cell. Crucially, cell health and functionality are preserved while there is a significant improvement on
the process time and costs. Avectas has demonstrated that the pilot system can successfully deliver clinically relevant cargo
to T cells. During this project, Avectas will scale and align Solupore to regulatory compliance enabling us to commercialise
it. The emerging and fast-growing cell immunotherapy market is set to be worth $20bn in 2020, with cell manufacturing
representing $5bn. Commercialisation of Solupore will take 1% of the €5bn market share by 2024 and will generate global
revenues for Avectas, building value for the company and creating highly skilled jobs which will result in a high-value,
knowledge-based EU company. There will be substantial European and global socio-economic impact on cancer patients
living longer, better quality lives.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
W23 F2H6 Kildare
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.